{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:51:03Z","timestamp":1793731863326,"version":"4.6.1"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:00:00Z","timestamp":1720742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:00:00Z","timestamp":1720742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010109","name":"Medical University of Graz","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010109","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose and objective<\/jats:title>\n                    <jats:p>To develop expert consensus statements on multiparametric dose prescriptions for stereotactic body radiotherapy (SBRT) aligning with ICRU report\u00a091. These statements serve as a\u00a0foundational step towards harmonizing current SBRT practices and refining dose prescription and documentation requirements for clinical trial designs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>Based on the results of a\u00a0literature review by the working group, a\u00a0two-tier Delphi consensus process was conducted among 24\u00a0physicians and physics experts from three European countries. The degree of consensus was predefined for overarching (OA) and organ-specific (OS) statements (\u2265\u202f80%, 60\u201379%, &lt;\u202f60% for high, intermediate, and poor consensus, respectively). Post-first round statements were refined in a\u00a0live discussion for the second round of the Delphi process.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Experts consented on a\u00a0total of 14\u00a0OA and 17\u00a0OS statements regarding SBRT of primary and secondary lung, liver, pancreatic, adrenal, and kidney tumors regarding dose prescription, target coverage, and organ at risk dose limitations. Degree of consent was\u202f\u2265\u200980% in 79% and 41% of OA and OS statements, respectively, with higher consensus for lung compared to the upper abdomen. In round\u00a02, the degree of consent was\u202f\u2265\u200980 to 100% for OA and 88% in OS statements. No consensus was reached for dose escalation to liver metastases after chemotherapy (47%) or single-fraction SBRT for kidney primaries (13%). In round\u00a02, no statement had 60\u201379% consensus.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In 29\u00a0of 31\u00a0statements a\u00a0high consensus was achieved after a\u00a0two-tier Delphi process and one statement (kidney) was clearly refused. The Delphi process was able to achieve a\u00a0high degree of consensus for SBRT dose prescription. In summary, clear recommendations for both OA and OS could be defined. This contributes significantly to harmonization of SBRT practice and facilitates dose prescription and reporting in clinical trials investigating SBRT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00066-024-02254-2","type":"journal-article","created":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T13:01:36Z","timestamp":1720789296000},"page":"737-750","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Dose prescription for stereotactic body radiotherapy: general and organ-specific consensus statement from the DEGRO\/DGMP Working Group Stereotactic Radiotherapy and Radiosurgery"],"prefix":"10.1007","volume":"200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6780-2820","authenticated-orcid":false,"given":"Thomas B.","family":"Brunner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"Boda-Heggemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"B\u00fcrgy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Corradini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute Karin","family":"Dieckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Gawish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Gerum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Gkika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Grohmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane","family":"H\u00f6rner-Rieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Kirste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer J.","family":"Klement","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Moustakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Nestle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Niyazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"R\u00fchle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie-Tanadini","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Zurl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Wittig-Sauerwein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Blanck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,12]]},"reference":[{"key":"2254_CR1","series-title":"ICRU Report 91, Prescribing, Recording, and Reporting of Stereotactic Treatments with Small Photon Beams. In","volume-title":"Bethesda, MD: International Commission on Radiation Units & Measurements","author":"L Seuntjens","year":"2017","unstructured":"Seuntjens\u00a0L, Lartigau\u00a0EF, Cora\u00a0S (2017) Bethesda, MD: International Commission on Radiation Units & Measurements. ICRU Report 91, Prescribing, Recording, and Reporting of Stereotactic Treatments with Small Photon Beams. In, vol 91"},{"key":"2254_CR2","doi-asserted-by":"crossref","unstructured":"Wilke L, Andratschke N, Blanck O, Brunner TB, Combs SE, Grosu AL, Moustakis C, Schmitt D, Baus WW, Guckenberger M (2019) ICRU report 91 on prescribing, recording, and reporting of stereotactic treatments with small photon beams: Statement from the DEGRO\/DGMP working group stereotactic radiotherapy and radiosurgery. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al] 195(3):193\u2013198","DOI":"10.1007\/s00066-018-1416-x"},{"key":"2254_CR3","doi-asserted-by":"crossref","unstructured":"Guckenberger M, Baus WW, Blanck O, Combs SE, Debus J, Engenhart-Cabillic R, Gauer T, Grosu AL, Schmitt D, Tanadini-Lang S et al (2020) Definition and quality requirements for stereotactic radiotherapy: consensus statement from the DEGRO\/DGMP Working Group Stereotactic Radiotherapy and Radiosurgery. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al] 196(5):417\u2013420","DOI":"10.1007\/s00066-020-01603-1"},{"key":"2254_CR4","doi-asserted-by":"crossref","unstructured":"Schmitt D, Blanck O, Gauer T, Fix MK, Brunner TB, Fleckenstein J, Loutfi-Krauss B, Manser P, Werner R, Wilhelm ML et al (2020) Technological quality requirements for stereotactic radiotherapy: Expert review group consensus from the DGMP Working Group for Physics and Technology in Stereotactic Radiotherapy. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al] 196(5):421\u2013443","DOI":"10.1007\/s00066-020-01583-2"},{"issue":"8","key":"2254_CR5","first-page":"759","volume":"198","author":"T Brunner","year":"2022","unstructured":"Brunner\u00a0T (2022) A story of hypofractionation and the \u201cTable on the Wall\u201d]. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft. Et Al 198(8):759\u2013760","journal-title":"Et Al"},{"key":"2254_CR6","doi-asserted-by":"crossref","unstructured":"Moustakis C, Blanck O, Ebrahimi Tazehmahalleh F, Ka Heng Chan M, Ernst I, Krieger T, Duma MN, Oechsner M, Ganswindt U, Heinz C et al (2017) Planning benchmark study for SBRT of early stage NSCLC: Results of the DEGRO Working Group Stereotactic Radiotherapy. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al] 193(10):780\u2013790","DOI":"10.1007\/s00066-017-1151-8"},{"key":"2254_CR7","doi-asserted-by":"crossref","unstructured":"Wilke L, Moustakis C, Blanck O, Albers D, Albrecht C, Avcu Y, Boucenna R, Buchauer K, Etzelstorfer T, Henkenberens C et al (2021) Improving interinstitutional and intertechnology consistency of pulmonary SBRT by dose prescription to the mean internal target volume dose. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al] 197(9):836\u2013846","DOI":"10.1007\/s00066-021-01799-w"},{"issue":"1","key":"2254_CR8","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ijrobp.2022.01.008","volume":"113","author":"C Moustakis","year":"2022","unstructured":"Moustakis\u00a0C, Blanck\u00a0O, Chan\u00a0MKH, Boda-Heggemann\u00a0J, Andratschke\u00a0N, Duma\u00a0MN, Albers\u00a0D, Baumer\u00a0C, Fehr\u00a0R, Korber\u00a0SA et\u00a0al (2022) Planning Benchmark Study for Stereotactic Body Radiation Therapy of Liver Metastases: Results of the DEGRO\/DGMP Working Group on Stereotactic Radiation Therapy and Radiosurgery. Int J Radiat Oncol Biol Phys 113(1):214\u2013227","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2254_CR9","doi-asserted-by":"crossref","unstructured":"Moustakis C, Blanck O, Grohmann M, Malek AH, Albers D, Bathen B, Barbiero S, Bartels D, Broggi S, Borzi GR et\u00a0al (2024) Planning benchmark study for stereotactic body radiation therapy of pancreas carcinomas with simultaneously integrated boost and protection: results of the DEGRO\/DGMP Working Group on stereotactic radiation therapy and radiosurgery. Int J Radiat Oncol Biol Phys","DOI":"10.1016\/j.ijrobp.2024.08.038"},{"key":"2254_CR10","unstructured":"Ashford N, Simpson V, Armstead J (1966) I don\u2019t need no doctor. In: A\u00a0Man and His Soul. Charles R (ed), Ashford"},{"issue":"3","key":"2254_CR11","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.radonc.2015.09.008","volume":"118","author":"M Guckenberger","year":"2016","unstructured":"Guckenberger\u00a0M, Klement\u00a0RJ, Allgauer\u00a0M, Andratschke\u00a0N, Blanck\u00a0O, Boda-Heggemann\u00a0J, Dieckmann\u00a0K, Duma\u00a0M, Ernst\u00a0I, Ganswindt\u00a0U et\u00a0al (2016) Local tumor control probability modeling of primary and secondary lung tumors in stereotactic body radiotherapy. Radiother Oncol 118(3):485\u2013491","journal-title":"Radiother Oncol"},{"issue":"3","key":"2254_CR12","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.ijrobp.2020.03.005","volume":"107","author":"RJ Klement","year":"2020","unstructured":"Klement\u00a0RJ, Sonke\u00a0JJ, Allgauer\u00a0M, Andratschke\u00a0N, Appold\u00a0S, Belderbos\u00a0J, Belka\u00a0C, Blanck\u00a0O, Dieckmann\u00a0K, Eich\u00a0HT et\u00a0al (2020) Correlating Dose Variables with Local Tumor Control in Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer: A\u00a0Modeling Study on 1500 Individual Treatments. Int J Radiat Oncol Biol Phys 107(3):579\u2013586","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2254_CR13","doi-asserted-by":"crossref","unstructured":"Guckenberger M, Andratschke N, Alheit H, Holy R, Moustakis C, Nestle U, Sauer O, Deutschen Gesellschaft fur R (2014) Definition of stereotactic body radiotherapy: principles and practice for the treatment of stage\u00a0I non-small cell lung cancer. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al] 190(1):26\u201333","DOI":"10.1007\/s00066-013-0450-y"},{"key":"2254_CR14","doi-asserted-by":"crossref","unstructured":"Sterzing F, Brunner TB, Ernst I, Baus WW, Greve B, Herfarth K, Guckenberger M (2014) Stereotactic body radiotherapy for liver tumors: principles and practical guidelines of the DEGRO Working Group on Stereotactic Radiotherapy. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al] 190(10):872\u2013881","DOI":"10.1007\/s00066-014-0714-1"},{"key":"2254_CR15","doi-asserted-by":"crossref","unstructured":"Panje C, Andratschke N, Brunner TB, Niyazi M, Guckenberger M (2016) Stereotactic body radiotherapy for renal cell cancer and pancreatic cancer: Literature review and practice recommendations of the DEGRO Working Group on Stereotactic Radiotherapy. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al] 192(12):875\u2013885","DOI":"10.1007\/s00066-016-1053-1"},{"key":"2254_CR16","volume-title":"ASTRO clinical practice. Guideline methodology guide. In","author":"C Patton","year":"2019","unstructured":"Patton\u00a0C, Bradfield\u00a0L (2019) ASTRO clinical practice. Guideline methodology guide. In"},{"issue":"25","key":"2254_CR17","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.1200\/JCO.2012.42.0489","volume":"30","author":"DA Loblaw","year":"2012","unstructured":"Loblaw\u00a0DA, Prestrud\u00a0AA, Somerfield\u00a0MR, Oliver\u00a0TK, Brouwers\u00a0MC, Nam\u00a0RK, Lyman\u00a0GH, Basch\u00a0E, Americal Society of Clinical Oncology Clinical Practice G (2012) American Society of Clinical Oncology Clinical Practice Guidelines: formal systematic review-based consensus methodology. J\u00a0Clin Oncol 30(25):3136\u20133140","journal-title":"J Clin Oncol"},{"key":"2254_CR18","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ejca.2023.02.015","volume":"185","author":"TE Kroese","year":"2023","unstructured":"Kroese\u00a0TE, van Laarhoven\u00a0HWM, Schoppman\u00a0SF, Deseyne\u00a0P, van Cutsem\u00a0E, Haustermans\u00a0K, Nafteux\u00a0P, Thomas\u00a0M, Obermannova\u00a0R, Mortensen\u00a0HR et\u00a0al (2023) Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: A\u00a0Delphi consensus study in Europe. Eur J Cancer 185:28\u201339","journal-title":"Eur J Cancer"},{"issue":"1","key":"2254_CR19","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ijrobp.2021.09.027","volume":"112","author":"R Timmerman","year":"2022","unstructured":"Timmerman\u00a0R (2022) A\u00a0Story of Hypofractionation and the Table on the Wall. Int J Radiat Oncol Biol Phys 112(1):4\u201321. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.09.027","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"2254_CR20","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.clon.2022.02.010","volume":"34","author":"P Diez","year":"2022","unstructured":"Diez P, Hanna GG, Aitken KL, van As N, Carver A, Colaco RJ, Conibear J, Dunne EM, Eaton DJ, Franks KN et al (2022) UK 2022 Consensus on Normal Tissue Dose-Volume Constraints for Oligometastatic, Primary Lung and Hepatocellular Carcinoma Stereotactic Ablative Radiotherapy. Clin Oncol (R\u00a0Coll Radiol) 34(5):288\u2013300. https:\/\/doi.org\/10.1016\/j.clon.2022.02.010","journal-title":"Clin Oncol (R\u00a0Coll Radiol)"},{"issue":"1","key":"2254_CR21","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.radonc.2016.10.024","volume":"122","author":"DA Toesca","year":"2017","unstructured":"Toesca\u00a0DA, Osmundson\u00a0EC, Eyben\u00a0RV, Shaffer\u00a0JL, Lu\u00a0P, Koong\u00a0AC, Chang\u00a0DT (2017) Central liver toxicity after SBRT: An expanded analysis and predictive nomogram. Radiother Oncol 122(1):130\u2013136. https:\/\/doi.org\/10.1016\/j.radonc.2016.10.024","journal-title":"Radiother Oncol"},{"issue":"2","key":"2254_CR22","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.radonc.2017.01.013","volume":"123","author":"RJ Klement","year":"2017","unstructured":"Klement\u00a0RJ, Guckenberger\u00a0M, Alheid\u00a0H, Allgauer\u00a0M, Becker\u00a0G, Blanck\u00a0O, Boda-Heggemann\u00a0J, Brunner\u00a0T, Duma\u00a0M, Gerum\u00a0S et\u00a0al (2017) Stereotactic body radiotherapy for oligo-metastatic liver disease\u2014Influence of pre-treatment chemotherapy and histology on local tumor control. Radiother Oncol 123(2):227\u2013233. https:\/\/doi.org\/10.1016\/j.radonc.2017.01.013","journal-title":"Radiother Oncol"},{"issue":"3","key":"2254_CR23","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.radonc.2014.05.002","volume":"111","author":"S Culleton","year":"2014","unstructured":"Culleton\u00a0S, Jiang\u00a0H, Haddad\u00a0CR, Kim\u00a0J, Brierley\u00a0J, Brade\u00a0A, Ringash\u00a0J, Dawson\u00a0LA (2014) Outcomes following definitive stereotactic body radiotherapy for patients with Child-Pugh B or\u00a0C hepatocellular carcinoma. Radiother Oncol 111(3):412\u2013417. https:\/\/doi.org\/10.1016\/j.radonc.2014.05.002","journal-title":"Radiother Oncol"},{"issue":"12","key":"2254_CR24","doi-asserted-by":"publisher","first-page":"00656","DOI":"10.1016\/S1470-2045","volume":"23","author":"S Siva","year":"2022","unstructured":"Siva\u00a0S, Ali\u00a0M, Correa\u00a0RJM, Muacevic\u00a0A, Ponsky\u00a0L, Ellis\u00a0RJ, Lo\u00a0SS, Onishi\u00a0H, Swaminath\u00a0A, McLaughlin\u00a0M et\u00a0al (2022) 5\u2011year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney). Lancet Oncol 23(12):1508\u20131516. https:\/\/doi.org\/10.1016\/S1470-2045(22)00656-8","journal-title":"Lancet Oncol"},{"issue":"12","key":"2254_CR25","doi-asserted-by":"publisher","first-page":"00697","DOI":"10.1016\/S1470-2045","volume":"23","author":"T Mizowaki","year":"2022","unstructured":"Mizowaki\u00a0T (2022) SABR for primary renal cell carcinoma: single-fraction or multiple-fraction? Lancet Oncol 23(12):1476\u20131477. https:\/\/doi.org\/10.1016\/S1470-2045(22)00697-0","journal-title":"Lancet Oncol"},{"issue":"3","key":"2254_CR26","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/ijc.34017","volume":"151","author":"D Buergy","year":"2022","unstructured":"Buergy\u00a0D, Wurschmidt\u00a0F, Gkika\u00a0E, Horner-Rieber\u00a0J, Knippen\u00a0S, Gerum\u00a0S, Balermpas\u00a0P, Henkenberens\u00a0C, Voglhuber\u00a0T, Kornhuber\u00a0C et\u00a0al (2022) Stereotactic body radiotherapy of adrenal metastases\u2011A dose-finding study. Int J Cancer 151(3):412\u2013421","journal-title":"Int J Cancer"},{"issue":"6","key":"2254_CR27","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.surg.2003.08.005","volume":"134","author":"M Brauckhoff","year":"2003","unstructured":"Brauckhoff\u00a0M, Gimm\u00a0O, Thanh\u00a0PN, Bar\u00a0A, Ukkat\u00a0J, Brauckhoff\u00a0K, Bonsch\u00a0T, Dralle\u00a0H (2003) Critical size of residual adrenal tissue and recovery from impaired early postoperative adrenocortical function after subtotal bilateral adrenalectomy. Surgery 134(6):1020\u20131027 (discussion 1027\u20131028)","journal-title":"Surgery"},{"issue":"1","key":"2254_CR28","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.radonc.2013.09.005","volume":"109","author":"M Guckenberger","year":"2013","unstructured":"Guckenberger\u00a0M, Klement\u00a0RJ, Allgauer\u00a0M, Appold\u00a0S, Dieckmann\u00a0K, Ernst\u00a0I, Ganswindt\u00a0U, Holy\u00a0R, Nestle\u00a0U, Nevinny-Stickel\u00a0M et\u00a0al (2013) Applicability of the linear-quadratic formalism for modeling local tumor control probability in high dose per fraction stereotactic body radiotherapy for early stage non-small cell lung cancer. Radiother Oncol 109(1):13\u201320","journal-title":"Radiother Oncol"},{"issue":"1","key":"2254_CR29","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.radonc.2014.10.015","volume":"114","author":"TB Brunner","year":"2015","unstructured":"Brunner\u00a0TB, Nestle\u00a0U, Grosu\u00a0AL, Partridge\u00a0M (2015) SBRT in pancreatic cancer: what is the therapeutic window? Radiother Oncol 114(1):109\u2013116","journal-title":"Radiother Oncol"},{"issue":"7","key":"2254_CR30","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.3109\/0284186X.2013.813638","volume":"52","author":"ES Worm","year":"2013","unstructured":"Worm\u00a0ES, Hoyer\u00a0M, Fledelius\u00a0W, Hansen\u00a0AT, Poulsen\u00a0PR (2013) Variations in magnitude and directionality of respiratory target motion throughout full treatment courses of stereotactic body radiotherapy for tumors in the liver. Acta Oncol 52(7):1437\u20131444","journal-title":"Acta Oncol"},{"issue":"1","key":"2254_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/0284186X.2016.1246801","volume":"56","author":"D van der Merwe","year":"2017","unstructured":"van der Merwe\u00a0D, Van Dyk\u00a0J, Healy\u00a0B, Zubizarreta\u00a0E, Izewska\u00a0J, Mijnheer\u00a0B, Meghzifene\u00a0A (2017) Accuracy requirements and uncertainties in radiotherapy: a\u00a0report of the International Atomic Energy Agency. Acta Oncol 56(1):1\u20136","journal-title":"Acta Oncol"},{"issue":"1","key":"2254_CR32","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1186\/s12885-019-5767-1","volume":"19","author":"G Chen","year":"2019","unstructured":"Chen\u00a0G, Dong\u00a0B, Shan\u00a0G, Zhang\u00a0X, Tang\u00a0H, Li\u00a0Y, Wang\u00a0Z, Xu\u00a0W, Xu\u00a0G, Yan\u00a0G et\u00a0al (2019) Choice of immobilization of stereotactic body radiotherapy in lung tumor patient by BMI. Bmc Cancer 19(1):583","journal-title":"Bmc Cancer"},{"issue":"10","key":"2254_CR33","doi-asserted-by":"publisher","first-page":"3874","DOI":"10.1118\/1.2349696","volume":"33","author":"PJ Keall","year":"2006","unstructured":"Keall\u00a0PJ, Mageras\u00a0GS, Balter\u00a0JM, Emery\u00a0RS, Forster\u00a0KM, Jiang\u00a0SB, Kapatoes\u00a0JM, Low\u00a0DA, Murphy\u00a0MJ, Murray\u00a0BR et\u00a0al (2006) The management of respiratory motion in radiation oncology report of AAPM Task Group\u00a076. Med Phys 33(10):3874\u20133900","journal-title":"Med Phys"},{"issue":"4","key":"2254_CR34","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.ejmp.2012.04.006","volume":"29","author":"G Bouilhol","year":"2013","unstructured":"Bouilhol\u00a0G, Ayadi\u00a0M, Rit\u00a0S, Thengumpallil\u00a0S, Schaerer\u00a0J, Vandemeulebroucke\u00a0J, Claude\u00a0L, Sarrut\u00a0D (2013) Is abdominal compression useful in lung stereotactic body radiation therapy? A 4DCT and dosimetric lobe-dependent study. Phys Med 29(4):333\u2013340","journal-title":"Phys Med"},{"key":"2254_CR35","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1748-717X-7-16","volume":"7","author":"P Mancosu","year":"2012","unstructured":"Mancosu\u00a0P, Castiglioni\u00a0S, Reggiori\u00a0G, Catalano\u00a0M, Alongi\u00a0F, Pellegrini\u00a0C, Arcangeli\u00a0S, Tozzi\u00a0A, Lobefalo\u00a0F, Fogliata\u00a0A et\u00a0al (2012) Stereotactic body radiation therapy for liver tumours using flattening filter free beam: dosimetric and technical considerations. Radiat Oncol 7:16","journal-title":"Radiat Oncol"},{"key":"2254_CR36","doi-asserted-by":"publisher","first-page":"1273042","DOI":"10.3389\/fonc.2023.1273042","volume":"13","author":"S Zhang","year":"2023","unstructured":"Zhang\u00a0S, Zhan\u00a0W, Zeng\u00a0N, Yang\u00a0J, Xiong\u00a0M, Liao\u00a0W, Chen\u00a0N, Xiao\u00a0J (2023) Dosimetric comparison in sparing normal tissue dosage by using auto-SBRT planning in oligo liver tumors. Front Oncol 13:1273042","journal-title":"Front Oncol"},{"issue":"8","key":"2254_CR37","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1080\/02841860310013490","volume":"42","author":"L Papiez","year":"2003","unstructured":"Papiez\u00a0L, Timmerman\u00a0R, DesRosiers\u00a0C, Randall\u00a0M (2003) Extracranial stereotactic radioablation: physical principles. Acta Oncol 42(8):882\u2013894","journal-title":"Acta Oncol"},{"key":"2254_CR38","doi-asserted-by":"publisher","first-page":"102501","DOI":"10.1016\/j.ejmp.2022.11.005","volume":"105","author":"M Varasteh","year":"2023","unstructured":"Varasteh\u00a0M, Ali\u00a0A, Esteve\u00a0S, Jeevanandam\u00a0P, Gopfert\u00a0F, Irvine\u00a0DM, Hounsell\u00a0AR, McGarry\u00a0CK (2023) Patient specific evaluation of breathing motion induced interplay effects. Phys Med 105:102501","journal-title":"Phys Med"},{"issue":"5","key":"2254_CR39","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1118\/1.2896083","volume":"35","author":"LE Court","year":"2008","unstructured":"Court\u00a0LE, Wagar\u00a0M, Ionascu\u00a0D, Berbeco\u00a0R, Chin\u00a0L (2008) Management of the interplay effect when using dynamic MLC sequences to treat moving targets. Med Phys 35(5):1926\u20131931","journal-title":"Med Phys"},{"key":"2254_CR40","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ejmp.2017.07.025","volume":"40","author":"E Hubley","year":"2017","unstructured":"Hubley\u00a0E, Pierce\u00a0G (2017) The influence of plan modulation on the interplay effect in VMAT liver SBRT treatments. Phys Med 40:115\u2013121","journal-title":"Phys Med"},{"key":"2254_CR41","doi-asserted-by":"crossref","unstructured":"Brunner TB, Nestle U, Adebahr S, Gkika E, Wiehle R, Baltas D, Grosu AL (2016) Simultaneous integrated protection: A\u00a0new concept for high-precision radiation therapy. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al] 192(12):886\u2013894","DOI":"10.1007\/s00066-016-1057-x"},{"key":"2254_CR42","doi-asserted-by":"crossref","unstructured":"Simoni N, Micera R, Paiella S, Guariglia S, Zivelonghi E, Malleo G, Rossi G, Addari L, Giuliani T, Pollini T et al (2021) Hypofractionated Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost and Simultaneous Integrated Protection in Pancreatic Ductal Adenocarcinoma. Clin Oncol (R\u00a0Coll Radiol) 33(1):e31\u2013e38","DOI":"10.1016\/j.clon.2020.06.019"},{"issue":"1","key":"2254_CR43","first-page":"61","volume":"4","author":"E Maranzano","year":"2016","unstructured":"Maranzano\u00a0E, Draghini\u00a0L, Anselmo\u00a0P, Casale\u00a0M, Arcidiacono\u00a0F, Chirico\u00a0L, Italiani\u00a0M, Trippa\u00a0F (2016) Lung reirradiation with stereotactic body radiotherapy. J\u00a0Radiosurg SBRT 4(1):61\u201368","journal-title":"J Radiosurg SBRT"},{"issue":"1","key":"2254_CR44","doi-asserted-by":"publisher","first-page":"4590","DOI":"10.1038\/s41598-021-83210-3","volume":"11","author":"C John","year":"2021","unstructured":"John\u00a0C, Dal Bello\u00a0R, Andratschke\u00a0N, Guckenberger\u00a0M, Boda-Heggemann\u00a0J, Gkika\u00a0E, Mantel\u00a0F, Specht\u00a0HM, Stromberger\u00a0C, Zehentmayr\u00a0F et\u00a0al (2021) In-field stereotactic body radiotherapy (SBRT) reirradiation for pulmonary malignancies as a\u00a0multicentre analysis of the German Society of Radiation Oncology (DEGRO). Sci Rep 11(1):4590","journal-title":"Sci Rep"},{"key":"2254_CR45","first-page":"85","volume":"28","author":"R Kinj","year":"2021","unstructured":"Kinj\u00a0R, Casutt\u00a0A, Bennassi\u00a0A, Bouchaab\u00a0H, Vallet\u00a0V, Lovis\u00a0A, Ozsahin\u00a0M (2021) Stereotactic lung reirradiation for local relapse: A\u00a0case series. Clin Transl. Radiat Oncol 28:85\u201387","journal-title":"Radiat Oncol"},{"key":"2254_CR46","doi-asserted-by":"crossref","unstructured":"Gkika E, Strouthos I, Kirste S, Adebahr S, Schultheiss M, Bettinger D, Fritsch R, Brass V, Maruschke L, Neeff HP et al (2019) Repeated SBRT for in- and out-of-field recurrences in the liver. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al] 195(3):246\u2013253","DOI":"10.1007\/s00066-018-1385-0"},{"issue":"10","key":"2254_CR47","doi-asserted-by":"publisher","first-page":"e886","DOI":"10.1002\/mp.15030","volume":"48","author":"IJ Das","year":"2021","unstructured":"Das\u00a0IJ, Francescon\u00a0P, Moran\u00a0JM, Ahnesjo\u00a0A, Aspradakis\u00a0MM, Cheng\u00a0CW, Ding\u00a0GX, Fenwick\u00a0JD, Saiful Huq\u00a0M, Oldham\u00a0M et\u00a0al (2021) Report of AAPM Task Group 155: Megavoltage photon beam dosimetry in small fields and non-equilibrium conditions. Med Phys 48(10):e886\u2013e921","journal-title":"Med Phys"},{"issue":"3","key":"2254_CR48","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.meddos.2018.10.004","volume":"44","author":"T Matsuoka","year":"2019","unstructured":"Matsuoka\u00a0T, Araki\u00a0F, Ohno\u00a0T, Sakata\u00a0J, Tominaga\u00a0H (2019) Dependence of volume dose indices on dose calculation algorithms for VMAT-SBRT plans for peripheral lung tumor. Med Dosim 44(3):284\u2013290","journal-title":"Med Dosim"},{"issue":"5","key":"2254_CR49","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.4103\/jcrt.jcrt_1740_21","volume":"19","author":"K Inoue","year":"2023","unstructured":"Inoue\u00a0K, Matsukawa\u00a0H, Kasai\u00a0Y, Edamitsu\u00a0K, Matsumoto\u00a0K, Suetsugu\u00a0Y, Hirose\u00a0TA, Fukunaga\u00a0JI, Shioyama\u00a0Y, Sasaki\u00a0T (2023) Difference in target dose distributions between Acuros XB and collapsed cone convolution\/superposition and the impact of the tumor locations in clinical cases of stereotactic ablative body radiotherapy for lung cancer. J\u00a0Cancer Res Ther 19(5):1261\u20131266","journal-title":"J Cancer Res Ther"},{"issue":"1","key":"2254_CR50","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.1016\/j.ijrobp.2012.08.039","volume":"85","author":"SF Kry","year":"2013","unstructured":"Kry\u00a0SF, Alvarez\u00a0P, Molineu\u00a0A, Amador\u00a0C, Galvin\u00a0J, Followill\u00a0DS (2013) Algorithms used in heterogeneous dose calculations show systematic differences as measured with the Radiological Physics Center\u2019s anthropomorphic thorax phantom used for RTOG credentialing. Int J Radiat Oncol Biol Phys 85(1):e95\u2013100","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"2254_CR51","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.ejmp.2015.04.002","volume":"31","author":"L Dunn","year":"2015","unstructured":"Dunn\u00a0L, Lehmann\u00a0J, Lye\u00a0J, Kenny\u00a0J, Kron\u00a0T, Alves\u00a0A, Cole\u00a0A, Zifodya\u00a0J, Williams\u00a0I (2015) National dosimetric audit network finds discrepancies in AAA lung inhomogeneity corrections. Phys Med 31(5):435\u2013441","journal-title":"Phys Med"},{"key":"2254_CR52","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.radonc.2019.06.008","volume":"138","author":"ML Lambrecht","year":"2019","unstructured":"Lambrecht\u00a0ML, Eaton\u00a0DJ, Sonke\u00a0JJ, Nestle\u00a0U, Peulen\u00a0H, Weber\u00a0DC, Verheij\u00a0M, Hurkmans\u00a0CW (2019) Results of a\u00a0multicentre dosimetry audit using a\u00a0respiratory phantom within the EORTC LungTech trial. Radiother Oncol 138:106\u2013113","journal-title":"Radiother Oncol"},{"key":"2254_CR53","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ejmp.2018.11.013","volume":"56","author":"M Josipovic","year":"2018","unstructured":"Josipovic\u00a0M, Persson\u00a0GF, Rydhog\u00a0JS, Smulders\u00a0B, Thomsen\u00a0JB, Aznar\u00a0MC (2018) Advanced dose calculation algorithms in lung cancer radiotherapy: Implications for SBRT and locally advanced disease in deep inspiration breath hold. Phys Med 56:50\u201357","journal-title":"Phys Med"},{"key":"2254_CR54","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.radonc.2021.03.006","volume":"159","author":"SF Kry","year":"2021","unstructured":"Kry\u00a0SF, Lye\u00a0J, Clark\u00a0CH, Andratschke\u00a0N, Dimitriadis\u00a0A, Followill\u00a0D, Howell\u00a0R, Hussein\u00a0M, Ishikawa\u00a0M, Kito\u00a0S et\u00a0al (2021) Report dose-to-medium in clinical trials where available; a\u00a0consensus from the Global Harmonisation Group to maximize consistency. Radiother Oncol 159:106\u2013111","journal-title":"Radiother Oncol"},{"issue":"4","key":"2254_CR55","first-page":"303","volume":"4","author":"C Snyder Karen","year":"2017","unstructured":"Snyder Karen\u00a0C, Liu\u00a0M, Zhao\u00a0B, Huang\u00a0Y, Ning\u00a0W, Chetty\u00a0IJ, Siddiqui\u00a0MS (2017) Investigating the dosimetric effects of grid size on dose calculation accuracy using volumetric modulated arc therapy in spine stereotactic radiosurgery. J\u00a0Radiosurg SBRT 4(4):303\u2013313","journal-title":"J Radiosurg SBRT"},{"key":"2254_CR56","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/1748-717X-8-149","volume":"8","author":"PS Kroon","year":"2013","unstructured":"Kroon\u00a0PS, Hol\u00a0S, Essers\u00a0M (2013) Dosimetric accuracy and clinical quality of Acuros XB and AAA dose calculation algorithm for stereotactic and conventional lung volumetric modulated arc therapy plans. Radiat Oncol 8:149","journal-title":"Radiat Oncol"},{"key":"2254_CR57","doi-asserted-by":"publisher","first-page":"101907","DOI":"10.1016\/j.compmedimag.2021.101907","volume":"90","author":"S Hernandez","year":"2021","unstructured":"Hernandez\u00a0S, Sjogreen\u00a0C, Gay\u00a0SS, Nguyen\u00a0C, Netherton\u00a0T, Olanrewaju\u00a0A, Zhang\u00a0LJ, Rhee\u00a0DJ, Mendez\u00a0JD, Court\u00a0LE et\u00a0al (2021) Development and dosimetric assessment of an automatic dental artifact classification tool to guide artifact management techniques in a\u00a0fully automated treatment planning workflow. Comput Med Imaging Graph 90:101907","journal-title":"Comput Med Imaging Graph"},{"key":"2254_CR58","unstructured":"Greco LTG, Vu K (2024) Dosimetric significance of manual density overrides in oropharyngeal cancer. Med Dosim"},{"key":"2254_CR59","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.radonc.2019.11.001","volume":"142","author":"EEC de Jong","year":"2020","unstructured":"de Jong\u00a0EEC, Guckenberger\u00a0M, Andratschke\u00a0N, Dieckmann\u00a0K, Hoogeman\u00a0MS, Milder\u00a0M, Moller\u00a0DS, Nyeng\u00a0TB, Tanadini-Lang\u00a0S, Lartigau\u00a0E et\u00a0al (2020) Variation in current prescription practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer: Recommendations for prescribing and recording according to the ACROP guideline and ICRU report 91. Radiother Oncol 142:217\u2013223","journal-title":"Radiother Oncol"},{"issue":"7","key":"2254_CR60","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.jtho.2016.03.008","volume":"11","author":"H Tekatli","year":"2016","unstructured":"Tekatli\u00a0H, Haasbeek\u00a0N, Dahele\u00a0M, De Haan\u00a0P, Verbakel\u00a0W, Bongers\u00a0E, Hashemi\u00a0S, Nossent\u00a0E, Spoelstra\u00a0F, de Langen\u00a0AJ et\u00a0al (2016) Outcomes of Hypofractionated High-Dose Radiotherapy in Poor-Risk Patients with \u201cUltracentral\u201d Non-Small Cell Lung Cancer. J\u00a0Thorac Oncol 11(7):1081\u20131089","journal-title":"J Thorac Oncol"},{"issue":"7","key":"2254_CR61","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/j.jtho.2021.03.019","volume":"16","author":"K Lindberg","year":"2021","unstructured":"Lindberg\u00a0K, Grozman\u00a0V, Karlsson\u00a0K, Lindberg\u00a0S, Lax\u00a0I, Wersall\u00a0P, Persson\u00a0GF, Josipovic\u00a0M, Khalil\u00a0AA, Moeller\u00a0DS et\u00a0al (2021) The HILUS-Trial\u2011a Prospective Nordic Multicenter Phase\u00a02 Study of Ultracentral Lung Tumors Treated With Stereotactic Body Radiotherapy. J\u00a0Thorac Oncol 16(7):1200\u20131210","journal-title":"J Thorac Oncol"},{"issue":"2","key":"2254_CR62","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.radonc.2018.07.001","volume":"129","author":"JH Chang","year":"2018","unstructured":"Chang\u00a0JH, Poon\u00a0I, Erler\u00a0D, Zhang\u00a0L, Cheung\u00a0P (2018) The safety and effectiveness of stereotactic body radiotherapy for central versus ultracentral lung tumors. Radiother Oncol 129(2):277\u2013283","journal-title":"Radiother Oncol"},{"key":"2254_CR63","doi-asserted-by":"crossref","unstructured":"Giuliani ME, Filion EJ, Faria S, Kundapur V, Vu TTT, Lok BH, Raman S, Bahig H, Laba JM, Lang P et al (2023) Stereotactic Radiation for Ultra-Central Non-Small Cell Lung Cancer: A\u00a0Safety and Efficacy Trial (SUNSET). In ASTRO Annual Meeting: January\u00a001, 2024 2023, San Diego, USA, Elsevier, E2","DOI":"10.1016\/j.ijrobp.2023.10.049"},{"key":"2254_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.05.366","author":"A Levy","year":"2024","unstructured":"Levy A, Adebahr S, Hurkmans C, Ahmed M, Ahmad S, Guckenberger M, Geets X, Lievens Y, Lambrecht M, Pourel N, Lewitzki V, Konopa K, Franks K, Dziadziuszko R, McDonald F, Fortpied C, Clementel E, Fournier B, Rizzo S, Fink C, Riesterer O, Peulen H, Andratschke N, McWilliam A, Gkika E, Schimek-Jasch T, Grosu AL, Le Pechoux C, Faivre-Finn C, Nestle U (2024) Stereotactic body radiotherapy for centrally located inoperable early-stage NSCLC: EORTC 22113-08113 LungTech phase II trial results. J Thorac Oncol. https:\/\/doi.org\/10.1016\/j.jtho.2024.05.366","journal-title":"J Thorac Oncol"},{"key":"2254_CR65","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13014-015-0567-5","volume":"11","author":"M Lambrecht","year":"2016","unstructured":"Lambrecht M, Melidis C, Sonke JJ, Adebahr S, Boellaard R, Verheij M, Guckenberger M, Nestle U, Hurkmans C (2016) Lungtech, a phase II EORTC trial of SBRT for centrally located lung tumours \u2013 a clinical physics perspective. Radiat Oncol 11:7. https:\/\/doi.org\/10.1186\/s13014-015-0567-5","journal-title":"Radiat Oncol"},{"issue":"4","key":"2254_CR66","doi-asserted-by":"publisher","first-page":"e529","DOI":"10.1016\/j.cllc.2018.04.001","volume":"19","author":"M Giuliani","year":"2018","unstructured":"Giuliani\u00a0M, Mathew\u00a0AS, Bahig\u00a0H, Bratman\u00a0SV, Filion\u00a0E, Glick\u00a0D, Louie\u00a0AV, Raman\u00a0S, Swaminath\u00a0A, Warner\u00a0A et\u00a0al (2018) SUNSET: Stereotactic Radiation for Ultracentral Non-Small-Cell Lung Cancer\u2011A Safety and Efficacy Trial. Clin Lung Cancer 19(4):e529\u2013e532","journal-title":"Clin Lung Cancer"},{"issue":"10","key":"2254_CR67","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1001\/jamaoncol.2021.2939","volume":"7","author":"S Siva","year":"2021","unstructured":"Siva S, Bressel M, Mai T, Le H, Vinod S, de Silva H, Macdonald S, Skala M, Hardcastle N, Rezo A et al (2021) Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II): The Trans Tasman Radiation Oncology Group\u00a013.01 Phase\u00a02 Randomized Clinical Trial. JAMA Oncol 7(10):1476\u20131485","journal-title":"JAMA Oncol"},{"issue":"2","key":"2254_CR68","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s00066-021-01811-3","volume":"198","author":"D Lubgan","year":"2022","unstructured":"Lubgan D, Semrau S, Lambrecht U, Gaipl US, Fietkau R (2022) 12 x 6\u202fGy stereotactic radiotherapy for lung tumors. Is there a\u00a0difference in response between lung metastases and primary bronchial carcinoma? Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al] 198(2):110\u2013122","journal-title":"Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft et al"},{"issue":"2","key":"2254_CR69","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.semradonc.2022.11.007","volume":"33","author":"A Das","year":"2023","unstructured":"Das\u00a0A, Giuliani\u00a0M, Bezjak\u00a0A (2023) Radiotherapy for Lung Metastases: Conventional to Stereotactic Body Radiation Therapy. Semin Radiat Oncol 33(2):172\u2013180","journal-title":"Semin Radiat Oncol"},{"key":"2254_CR70","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.radonc.2018.11.015","volume":"132","author":"TB Brunner","year":"2019","unstructured":"Brunner\u00a0TB, Blanck\u00a0O, Lewitzki\u00a0V, Abbasi-Senger\u00a0N, Momm\u00a0F, Riesterer\u00a0O, Duma\u00a0MN, Wachter\u00a0S, Baus\u00a0W, Gerum\u00a0S et\u00a0al (2019) Stereotactic body radiotherapy dose and its impact on local control and overall survival of patients for locally advanced intrahepatic and extrahepatic cholangiocarcinoma. Radiother Oncol 132:42\u201347","journal-title":"Radiother Oncol"},{"issue":"5","key":"2254_CR71","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.ijrobp.2016.03.050","volume":"95","author":"KA Ahmed","year":"2016","unstructured":"Ahmed\u00a0KA, Caudell\u00a0JJ, El-Haddad\u00a0G, Berglund\u00a0AE, Welsh\u00a0EA, Yue\u00a0B, Hoffe\u00a0SE, Naghavi\u00a0AO, Abuodeh\u00a0YA, Frakes\u00a0JM et\u00a0al (2016) Radiosensitivity Differences Between Liver Metastases Based on Primary Histology Suggest Implications for Clinical Outcomes After Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys 95(5):1399\u20131404","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2254_CR72","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.radonc.2021.12.018","volume":"167","author":"S Sheikh","year":"2022","unstructured":"Sheikh\u00a0S, Chen\u00a0H, Sahgal\u00a0A, Poon\u00a0I, Erler\u00a0D, Badellino\u00a0S, Dagan\u00a0R, Foote\u00a0MC, Louie\u00a0AV, Redmond\u00a0KJ et\u00a0al (2022) An analysis of a\u00a0large multi-institutional database reveals important associations between treatment parameters and clinical outcomes for stereotactic body radiotherapy (SBRT) of oligometastatic colorectal cancer. Radiother Oncol 167:187\u2013194","journal-title":"Radiother Oncol"},{"key":"2254_CR73","doi-asserted-by":"crossref","unstructured":"Pan CC, Kavanagh BD, Dawson LA, Li XA, Das SK, Miften M, Ten Haken RK (2010) Radiation-associated liver injury. Int J Radiat Oncol Biol Phys 76(3 Suppl):S94\u2013100","DOI":"10.1016\/j.ijrobp.2009.06.092"},{"issue":"2","key":"2254_CR74","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ijrobp.2023.08.015","volume":"118","author":"SH Bae","year":"2024","unstructured":"Bae\u00a0SH, Chun\u00a0SJ, Chung\u00a0JH, Kim\u00a0E, Kang\u00a0JK, Jang\u00a0WI, Moon\u00a0JE, Roquette\u00a0I, Mirabel\u00a0X, Kimura\u00a0T et\u00a0al (2024) Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Meta-Analysis and International Stereotactic Radiosurgery Society Practice Guidelines. Int J Radiat Oncol Biol Phys 118(2):337\u2013351","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"2254_CR75","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.ijrobp.2018.04.011","volume":"101","author":"LJ Murray","year":"2018","unstructured":"Murray\u00a0LJ, Sykes\u00a0J, Brierley\u00a0J, Kim\u00a0JJ, Wong\u00a0RKS, Ringash\u00a0J, Craig\u00a0T, Velec\u00a0M, Lindsay\u00a0P, Knox\u00a0JJ et\u00a0al (2018) Baseline Albumin-Bilirubin (ALBI) Score in Western Patients With Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy (SBRT). Int J Radiat Oncol Biol Phys 101(4):900\u2013909","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2254_CR76","doi-asserted-by":"crossref","unstructured":"Gkika E, Bettinger D, Krafft L, Schultheiss M, Neeff HP, Maruschke L, Schulenburg M, Adebahr S, Kirste S, Nestle U et al (2018) The role of albumin-bilirubin grade and inflammation-based index in patients with hepatocellular carcinoma treated with stereotactic body radiotherapy. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al] 194(5):403\u2013413","DOI":"10.1007\/s00066-017-1256-0"},{"issue":"3","key":"2254_CR77","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.prro.2022.11.013","volume":"13","author":"T Craig","year":"2023","unstructured":"Craig\u00a0T, Xiao\u00a0Y, McNulty\u00a0S, Dawson\u00a0LA (2023) Insights From Image Guided Radiation Therapy Credentialing for the NRG Oncology RTOG 1112 Liver Stereotactic Body Radiation Therapy Trial. Pract Radiat Oncol 13(3):239\u2013245","journal-title":"Pract Radiat Oncol"},{"issue":"5","key":"2254_CR78","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/j.ijrobp.2022.09.002","volume":"114","author":"LA Dawson","year":"2022","unstructured":"Dawson\u00a0LA, Winter\u00a0K, Knox\u00a0J, Zhu\u00a0AX, Krishnan\u00a0S, Guha\u00a0C, Kachnic\u00a0LA, Gillin\u00a0MT, Hong\u00a0TS, Craig\u00a0T et\u00a0al (2022) NRG\/RTOG 1112: Randomized Phase\u00a0III Study of Sorafenib vs. Stereotactic Body Radiation Therapy (SBRT) Followed by Sorafenib in Hepatocellular Carcinoma (HCC) (NCT01730937). Int J Radiat Oncol Biol Phys 114(5):1057","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2254_CR79","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.radonc.2020.07.052","volume":"154","author":"TB Brunner","year":"2021","unstructured":"Brunner\u00a0TB, Haustermans\u00a0K, Huguet\u00a0F, Morganti\u00a0AG, Mukherjee\u00a0S, Belka\u00a0C, Krempien\u00a0R, Hawkins\u00a0MA, Valentini\u00a0V, Roeder\u00a0F (2021) ESTRO ACROP guidelines for target volume definition in pancreatic cancer. Radiother Oncol 154:60\u201369","journal-title":"Radiother Oncol"},{"issue":"3","key":"2254_CR80","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.ijrobp.2008.01.051","volume":"72","author":"D Schellenberg","year":"2008","unstructured":"Schellenberg\u00a0D, Goodman\u00a0KA, Lee\u00a0F, Chang\u00a0S, Kuo\u00a0T, Ford\u00a0JM, Fisher\u00a0GA, Quon\u00a0A, Desser\u00a0TS, Norton\u00a0J et\u00a0al (2008) Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 72(3):678\u2013686","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"2254_CR81","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/cncr.29161","volume":"121","author":"JM Herman","year":"2015","unstructured":"Herman\u00a0JM, Chang\u00a0DT, Goodman\u00a0KA, Dholakia\u00a0AS, Raman\u00a0SP, Hacker-Prietz\u00a0A, Iacobuzio-Donahue\u00a0CA, Griffith\u00a0ME, Pawlik\u00a0TM, Pai\u00a0JS et\u00a0al (2015) Phase\u00a02 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer 121(7):1128\u20131137","journal-title":"Cancer"},{"issue":"3","key":"2254_CR82","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.prro.2019.11.005","volume":"10","author":"V Bernard","year":"2020","unstructured":"Bernard\u00a0V, Herman\u00a0JM (2020) Pancreas SBRT: Who, What, When, Where, and How. Pract Radiat Oncol 10(3):183\u2013185","journal-title":"Pract Radiat Oncol"},{"issue":"5","key":"2254_CR83","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.prro.2019.06.016","volume":"9","author":"M Palta","year":"2019","unstructured":"Palta\u00a0M, Godfrey\u00a0D, Goodman\u00a0KA, Hoffe\u00a0S, Dawson\u00a0LA, Dessert\u00a0D, Hall\u00a0WA, Herman\u00a0JM, Khorana\u00a0AA, Merchant\u00a0N et\u00a0al (2019) Radiation Therapy for Pancreatic Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. Pract Radiat Oncol 9(5):322\u2013332","journal-title":"Pract Radiat Oncol"},{"key":"2254_CR84","doi-asserted-by":"crossref","unstructured":"Gkika E, Adebahr S, Kirste S, Schimek-Jasch T, Wiehle R, Claus R, Wittel U, Nestle U, Baltas D, Grosu AL et al (2017) Stereotactic body radiotherapy (SBRT) in recurrent or oligometastatic pancreatic cancer: A\u00a0toxicity review of simultaneous integrated protection (SIP) versus conventional SBRT. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al] 193(6):433\u2013443","DOI":"10.1007\/s00066-017-1099-8"},{"key":"2254_CR85","doi-asserted-by":"publisher","first-page":"842402","DOI":"10.3389\/fonc.2022.842402","volume":"12","author":"M Michalet","year":"2022","unstructured":"Michalet\u00a0M, Bordeau\u00a0K, Cantaloube\u00a0M, Valdenaire\u00a0S, Debuire\u00a0P, Simeon\u00a0S, Portales\u00a0F, Draghici\u00a0R, Ychou\u00a0M, Assenat\u00a0E et\u00a0al (2022) Stereotactic MR-Guided Radiotherapy for Pancreatic Tumors: Dosimetric Benefit of Adaptation and First Clinical Results in a\u00a0Prospective Registry Study. Front Oncol 12:842402","journal-title":"Front Oncol"},{"key":"2254_CR86","first-page":"104","volume":"18","author":"A R\u00fchle","year":"2019","unstructured":"R\u00fchle\u00a0A, Andratschke\u00a0N, Siva\u00a0S, Guckenberger\u00a0M (2019) Is there a\u00a0role for stereotactic radiotherapy in the treatment of renal cell carcinoma? Clin Transl Radiat Oncol 18:104\u2013112","journal-title":"Clin Transl Radiat Oncol"},{"issue":"6","key":"2254_CR87","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.euf.2019.06.002","volume":"5","author":"RJM Correa","year":"2019","unstructured":"Correa\u00a0RJM, Louie\u00a0AV, Zaorsky\u00a0NG, Lehrer\u00a0EJ, Ellis\u00a0R, Ponsky\u00a0L, Kaplan\u00a0I, Mahadevan\u00a0A, Chu\u00a0W, Swaminath\u00a0A et\u00a0al (2019) The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A\u00a0Systematic Review and Meta-Analysis. Eur Urol Focus 5(6):958\u2013969","journal-title":"Eur Urol Focus"},{"issue":"5","key":"2254_CR88","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1002\/cncr.31156","volume":"124","author":"S Siva","year":"2018","unstructured":"Siva\u00a0S, Louie\u00a0AV, Warner\u00a0A, Muacevic\u00a0A, Gandhidasan\u00a0S, Ponsky\u00a0L, Ellis\u00a0R, Kaplan\u00a0I, Mahadevan\u00a0A, Chu\u00a0W et\u00a0al (2018) Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: A\u00a0report from the International Radiosurgery Oncology Consortium for Kidney (IROCK). Cancer 124(5):934\u2013942","journal-title":"Cancer"},{"key":"2254_CR89","unstructured":"National Comprehensive Cancer Network (2023) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Kidney Cancer Version\u00a01.2024\u2014June\u00a021, 2023"},{"key":"2254_CR90","unstructured":"(2023) Leitlinienprogramm Onkologie: S3-Leitlinie Diagnostik, Therapie und Nachsorge des Nierenzellkarzinoms, Langversion 4.0, Februar 2023"},{"issue":"2","key":"2254_CR91","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ijrobp.2023.06.208","volume":"117","author":"S Siva","year":"2023","unstructured":"Siva\u00a0S, Bressel\u00a0M, Sidhom\u00a0M, Sridharan\u00a0S, Vanneste\u00a0B, Davey\u00a0R, Ruben\u00a0J, Foroudi\u00a0F, Higgs\u00a0BG, Lin\u00a0C et\u00a0al (2023) TROG 15.03\/ANZUP International Multicenter Phase\u00a0II Trial of Focal Ablative STereotactic RAdiotherapy for Cancers of the Kidney (FASTRACK II). Int J Radiat Oncol Biol Phys 117(2):3","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2254_CR92","doi-asserted-by":"crossref","unstructured":"Siva S, Chesson B, Bressel M, Pryor D, Higgs B, Reynolds HM, Hardcastle N, Montgomery R, Vanneste B, Khoo V et al (2018) TROG 15.03 phase\u00a0II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney\u2014FASTRACK II. BMC Cancer 18(1):1030","DOI":"10.1186\/s12885-018-4916-2"},{"issue":"3","key":"2254_CR93","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/S1470-2045(24)00020-2","volume":"25","author":"S Siva","year":"2024","unstructured":"Siva\u00a0S, Bressel\u00a0M, Sidhom\u00a0M, Sridharan\u00a0S, Vanneste\u00a0BGL, Davey\u00a0R, Montgomery\u00a0R, Ruben\u00a0J, Foroudi\u00a0F, Higgs\u00a0B et\u00a0al (2024) Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a\u00a0non-randomised phase\u00a02\u00a0trial. Lancet Oncol 25(3):308\u2013316","journal-title":"Lancet Oncol"},{"issue":"5","key":"2254_CR94","doi-asserted-by":"publisher","first-page":"637","DOI":"10.2217\/fon.16.2","volume":"12","author":"S Siva","year":"2016","unstructured":"Siva\u00a0S, Ellis\u00a0RJ, Ponsky\u00a0L, Teh\u00a0BS, Mahadevan\u00a0A, Muacevic\u00a0A, Staehler\u00a0M, Onishi\u00a0H, Wersall\u00a0P, Nomiya\u00a0T (2016) Consensus statement from the International Radiosurgery Oncology Consortium for Kidney for primary renal cell carcinoma. Future Oncol 12(5):637\u2013645","journal-title":"Future Oncol"},{"key":"2254_CR95","doi-asserted-by":"crossref","unstructured":"Kirste S, R\u00fchle A, Zschiedrich S, Schultze-Seemann W, Jilg CA, Neumann-Haefelin E, Lo SS, Grosu AL, Kim E (2022) Stereotactic Body Radiotherapy for Renal Cell Carcinoma in Patients with Von Hippel-Lindau Disease-Results of a\u00a0Prospective Trial. Cancers (basel) 14(20)","DOI":"10.3390\/cancers14205069"},{"issue":"1","key":"2254_CR96","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/cen.14911","volume":"99","author":"J Herndon","year":"2023","unstructured":"Herndon\u00a0J, Hallemeier\u00a0C, Jethwa\u00a0K, Shariff\u00a0A, Bancos\u00a0I (2023) Radiation of bilateral adrenal metastases is associated with a\u00a0high risk of primary adrenal insufficiency. Clin Endocrinol (oxf) 99(1):35\u201342","journal-title":"Clin Endocrinol (oxf)"},{"issue":"2","key":"2254_CR97","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/ijc.33546","volume":"149","author":"D Buergy","year":"2021","unstructured":"Buergy\u00a0D, Wurschmidt\u00a0F, Gkika\u00a0E, Horner-Rieber\u00a0J, Knippen\u00a0S, Gerum\u00a0S, Balermpas\u00a0P, Henkenberens\u00a0C, Voglhuber\u00a0T, Kornhuber\u00a0C et\u00a0al (2021) Stereotactic or conformal radiotherapy for adrenal metastases: Patient characteristics and outcomes in a\u00a0multicenter analysis. Int J Cancer 149(2):358\u2013370","journal-title":"Int J Cancer"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-024-02254-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-024-02254-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-024-02254-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T19:52:28Z","timestamp":1732391548000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-024-02254-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,12]]},"references-count":97,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["2254"],"URL":"https:\/\/doi.org\/10.1007\/s00066-024-02254-2","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,12]]},"assertion":[{"value":"29 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"TB: AstraZeneca (speaker), Onconovum (speaker), Heckel (research support), Brainlab (research support), Varian (educational); JBH: EBAMed SA (Consultant), Elekta (Research), AstraZeneca (Education \/ Meeting Faculty); DB: Siemens AG (speaker), NB Capital Research GmbH (speaker), NB Capital ApS (speaker), PharmaMar GmbH (speaker); (SC): Elekta, (speakers bureau), Brainlab (research); UN: (AstraZeneca, research) MN: (Brainlab (speaker, research), Astrazeneca (speaker)) BZ: (EBG MedAustron GmbH (Advisory Board), Elsevier (Advisory Board)); AR: Novocure (speaker), Merck (speaker). Ute Karin Dieckmann, Ahmed Gawish, Sabine Gerum, Eleni Gkika, Maximilian Grohmann, Juliane H\u00f6rner-Rieber, Simon Kirste, Rainer J. Klement, Christos Moustakis, Stephanie-Tanadini Lang, Peter Winkler, Andrea Wittig-Sauerwein, and Oliver Blanck declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}